Inhibition of REV‐ERBs stimulates microglial amyloid‐beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer’s disease

A promising new therapeutic target for the treatment of Alzheimer's disease (AD) is the circadian system. Although patients with AD are known to have abnormal circadian rhythms and suffer sleep disturbances, the role of the molecular clock in regulating amyloid‐beta (Aβ) pathology is still poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jiyeon, Kim, Do Eon, Griffin, Percy, Sheehan, Patrick W., Kim, Dong‐Hou, Musiek, Erik S, Yoon, Seung‐Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996949/
https://www.ncbi.nlm.nih.gov/pubmed/31800167
http://dx.doi.org/10.1111/acel.13078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996949/
https://www.ncbi.nlm.nih.gov/pubmed/31800167
http://dx.doi.org/10.1111/acel.13078

Ejemplares similares